In active AML, outcomes superior for allo-HCT with unrelated donor than for cord blood transplantation
Postinduction, median nadir serum asparaginase activity was similar in patients receiving either drug, suggesting a need for dosing optimization.
Overall survival 1.5 months; survival improved for those receiving chemotherapy
A retrospective cohort study from St Jude Children’s Research Hospital sought to determine how long-term effects of treatment have evolved for survivors of pediatric ALL.
What is the role of the clinician in managing financial toxicity?